Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

Phase 2 Study to Explore the Efficacy of Novel Proteasome Inhibitor in

Patients with Relapsed and Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif. and NORWALK, Conn., Aug. 15 /PRNewswire/ -- The Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today announced the enrollment of the first patient in a multi-center Phase 2 clinical trial to study Proteolix's potent and selective proteasome inhibitor, carfilzomib (PR-171), in patients with relapsed and refractory multiple myeloma. Ten MMRC Member Institutions will participate in the study, under the MMRC leadership of Melissa Alsina, MD, H. Lee Moffitt Cancer Center & Research Institute. The nine additional sites are the City of Hope, Emory University, Cancer Center at Hackensack University Medical Center, Mayo Clinic, Princess Margaret/University Health Network, Saint Vincent's Comprehensive Cancer Center, University of Michigan, and Washington University.

The MMRC is the only research model of its kind that brings together 13 leading academic institutions to accelerate the development of novel and combination treatments for multiple myeloma, an incurable cancer of the plasma cell.

"Proteasome inhibitors are an important class of drugs for the treatment of multiple myeloma and we are proud to work with Proteolix to advance the clinical development of carfilzomib," said Kathy Giusti, Founder and Chief Executive Officer of the MMRC. "This trial and the others the MMRC are facilitating underscore our commitment to bring better, more effective treatments to myeloma patients as quickly as possible."

The trial will evaluate the overall response rate (ORR) for two cycles of carfilzomib in patients with multiple myeloma who have previously received specific FDA-approved therapies, have relapsed after two or more of such therapies, and are refractory to the most recently received therapy. Secondary objectives of this study include safety and tolerability, clinica
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. Mx4000 Multiplex Quantitative PCR System*,PPP
2. QIAGEN Multiplex PCR Handbook
3. Fully automated DNA purification and efficient multiplex PCR for analysis of microsatellite loci
4. QIAGEN Multiplex PCR Kit
5. Measuring multiple apoptosis parameters with the Agilent 2100 bioanalyzer
6. Microfluidic analysis of multiplex PCR products for the genotyping of Helicobacter pylori
7. A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis
8. Real-Time Multiplex PCR from Genomic DNA Using the iCycler iQ Detection System
9. Correlation of Bio-Plex Suspension Array Reader Validation With Multiplex Cytokine Assay Performance, Rev A
10. Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B
11. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 The Pistoia Alliance, ... lowering the barriers to innovation in life sciences ... of Carmen Nitsche as Executive Director Business Development ... its global reach. , Carmen joins the Pistoia ... Corporate Development. At Accelrys, she managed various life ...
(Date:9/16/2014)... 2014 This report analyzes the worldwide markets for ... Hardware, and Biocontent. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... of World. Annual estimates and forecasts are provided for the ... provided for these markets. Market data and analytics are derived ...
(Date:9/16/2014)... September 16, 2014 --The emerging field of molecular ... the next level, enabling the construction of tiny ... devices, individual molecules would take on the roles ... , A team of researchers from five Japanese ... for use in small-scale electronics: a molecule called ...
(Date:9/16/2014)... 16, 2014 BlueInGreen® , ... efficient method for delivering dissolved gases into liquids, ... as a manufacturer’s representative firm to its ... products for municipal water and wastewater applications in ... H2Flow was founded in 1992 and serves Quebec ...
Breaking Biology Technology:Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23The future face of molecular electronics 2BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2
... 2008 - Vol. 299. No. 8: ,Venous Thromboembolism and ... Administration for the Treatment of Cancer-Associated ... believes that,the conclusions of a study published in the ... Medical Association (JAMA) by Bennett, et al, do,not provide ...
... 26 CV Therapeutics,Inc. (Nasdaq: CVTX ) today reported ... 31, 2007., For the quarter ended December 31, 2007, ... per share. This compares to a net loss of,$68.1 million, ... and $34.2,million, or $0.58 per share, for the prior quarter ...
... REINACH, Switzerland, February 26 Arpida Ltd.,(SWX: ARPN) today ... (NDA) for intravenous iclaprim in its first indication,complicated Skin ... next few weeks., Arpida has agreed with the ... in a rolling process. Using a ,rolling NDA, allows ...
Cached Biology Technology:Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 2Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 3Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 4Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 5Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 4CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 5CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 7CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 8Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim 2Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim 3
(Date:9/16/2014)... rock hit the Yukatan peninsula near the site of the ... of TNT. It left a crater more than 150 km ... are widely accepted to have wiped out the dinosaurs and ... happened to the plants on which the dinosaurs fed? , ... Arizona reveals that the meteorite impact that spelled doom for ...
(Date:9/16/2014)... A complex web of interaction between viruses, bacteria, ... by a growing international collaboration between Matthew Sullivan, ... of Ecology and Evolutionary Biology and Steven Hallam ... Canada. , "Bacteria are drivers of nutrient ... said. "As the climate is changing, so are ...
(Date:9/16/2014)... Three years after the Hesperides vessel returned to Spain ... researchers have an increasingly clear picture of how the ... Specifically, the input of pollutants from the atmosphere is ... the most remote areas of the planet, and it ... findings are presented this week in CSIC Residence for ...
Breaking Biology News(10 mins):Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
... , May 30, 2013  Chiltern International Limited (Chiltern), a global ... Barbee to the position of Vice President, Global Biometrics. ... Chiltern stated: "We are extremely pleased to announce the promotion of ... to VP of Global Biometrics. In this role, Alecia will have ...
... for final exams might want to wait before pulling ... as their neurons are concerned. Carnegie Mellon University neuroscientists ... during which repeated exposure to a stimulus shrinks synapses. ... of the Journal of Neuroscience . It,s ...
... summit in Lough Erne, Northern Ireland, the German National ... science academies of the G8 member states and five ... state and government of the eight leading industrialised nations ... immediate future: drug-resistant infectious agents and sustainable development. The ...
Cached Biology News:Chiltern Announces The Promotion Of Alecia Barbee To VP, Global Biometrics 2Carnegie Mellon neuroscientists discover new phase of synaptic development 2The German National Academy of Sciences Leopoldina makes recommendations for the G8 summit 2
... screening, low melting point agarose where separation ... recommended for separation of nucleic acids less ... products. Micro ABgarose is also suited to ... blotting techniques. At a 3% concentration, Micro ...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
... Abpromise for all tested applications). ... derived from within residues 1 - 100 of ... is proprietary) (Peptide available as ... ID: 5453 Swiss Protein ...
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Biology Products: